1.25 mg Mounjaro: what is this dose for?

Is 1.25 mg Mounjaro a real dose you can be prescribed?

Not through any licensed route in the UK. The Mounjaro KwikPen is manufactured in six fixed strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Each pen delivers those doses once weekly over four weeks. There is no 1.25 mg version approved by the MHRA, and no 1.25 mg pen produced by Eli Lilly for the UK market.

Where does the figure come from? Compounding pharmacies (mostly operating outside regulated UK supply chains) have sold unlicensed tirzepatide preparations at various concentrations, including sub-2.5 mg doses. These products carry real risks: they are not subject to the same manufacturing standards, purity testing or clinical oversight as licensed medicines. The MHRA has been clear that unlicensed compounded GLP-1 preparations should not be used as substitutes for the licensed product. If you have been offered a 1.25 mg tirzepatide preparation by any supplier, that is a prompt to ask harder questions about their legitimacy.

The full picture of what licensed Mounjaro involves (strengths, schedule and how the KwikPen works) is covered in detail on the Mounjaro doses guide.

Why does licensed Mounjaro start at 2.5 mg rather than lower?

The starting dose exists to give your body time to adjust, not to begin meaningful weight reduction immediately. Tirzepatide slows gastric emptying and reduces appetite by acting on both GIP and GLP-1 receptors simultaneously, a mechanism that is more powerful than single-pathway medicines, but also one that can cause nausea, loose stools or fatigue in the early weeks if the dose moves too quickly.

A common misconception is that 2.5 mg is doing nothing and should be skipped or halved. In practice, the four weeks at this level are doing something important: training your gut to tolerate the medicine so that subsequent increases land with far fewer side effects. The practical guide to starting at this level explains what those first weeks typically feel like and what to watch for.

The MHRA-approved titration schedule, described in the Mounjaro Summary of Product Characteristics on the Electronic Medicines Compendium, increases the dose in 2.5 mg steps, typically every four weeks, up to a maximum of 15 mg. Every step is a prescriber decision. Patients who experience persistent side effects may stay at a lower dose for longer; that is a clinical call, not a failure.

What actually happens to weight loss at the 2.5 mg starter dose?

The SURMOUNT-1 trial, involving 2,539 adults with obesity, showed average weight reductions of around 20–21% at the 15 mg maintenance dose over 72 weeks. That figure is frequently quoted (and it is real) but it reflects a full treatment course including months at therapeutic doses, not the starting level.

At 2.5 mg, most people see little to no weight change in the first month. Appetite may begin to reduce; some people notice portion sizes naturally falling. But the primary job of the first pen is settling the system. If you are searching for evidence that the 1.25 mg tirzepatide dose produces meaningful loss, the honest answer is that there is no licensed clinical data to support it, the trial evidence, cited in NICE technology appraisal TA1026, was built on the licensed 2.5–15 mg schedule.

For a focused look at what the evidence says about early-dose effectiveness, the question of weight loss on the lowest dose is addressed separately, and whether any sub-licensed dose has clinical backing is examined directly.

What should you do if you have been offered a 1.25 mg dose?

Pause and verify. Check whether the supplier is registered with the GPhC at the pharmacy register, a legitimate UK online pharmacy will appear there with a premises number you can look up in seconds. If the supplier cannot be found, or is offering tirzepatide without a clinical consultation, walk away.

If you are already on licensed Mounjaro and wondering whether your dose could be split or reduced (perhaps because side effects are difficult) that is a conversation for your prescriber, not a decision to act on independently. Splitting a pen or diluting a dose at home carries unpredictable risks and voids any clinical oversight.

The weight-loss treatment overview covers how private prescribing through a regulated UK pharmacy works, including what a proper consultation involves. For pricing context on licensed treatment, the Mounjaro price comparison guide explains what legitimate private costs look like and what to make of prices that seem unusually low. At nume, every consultation is reviewed by a real clinician, a named GPhC-registered prescriber reads your answers the same day, not software processing a form.